Again, they are all fatty acids. As far as the Amarin v. AZN action, it had no merit, but neither did it merit the loss of capital and time defending. AZN will easily win whatever action comes their way regarding IP over Epanova in the future. We cover this extensively in our report.
Amarin, however, will not be so lucky, and we are confident they will lose in January.
News 
Market Data 
Discover 
AI
